| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 18/05/2023 | 14:00 | GlobeNewswire Inc. | Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 15/05/2023 | 16:03 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 01/05/2023 | 16:03 | Edgar (US Regulatory) | Annual Report to Security Holders (ars) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 01/05/2023 | 16:02 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 01/05/2023 | 16:01 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 28/04/2023 | 14:15 | GlobeNewswire Inc. | Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 14/04/2023 | 22:31 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 31/03/2023 | 14:31 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 30/03/2023 | 22:10 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 30/03/2023 | 22:01 | GlobeNewswire Inc. | Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 23/03/2023 | 13:30 | GlobeNewswire Inc. | Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 17/03/2023 | 13:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 07/03/2023 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 21/02/2023 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 15/02/2023 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 10/02/2023 | 23:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 10/02/2023 | 14:00 | GlobeNewswire Inc. | Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 04/01/2023 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023. | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 14/12/2022 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 08/11/2022 | 22:00 | GlobeNewswire Inc. | Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 08/11/2022 | 14:30 | GlobeNewswire Inc. | PCS12852 Improves Gastric Emptying in Gastroparesis Patients | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 02/11/2022 | 13:30 | GlobeNewswire Inc. | Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 01/11/2022 | 13:30 | GlobeNewswire Inc. | Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 05/10/2022 | 22:41 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 15/09/2022 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 07/09/2022 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022 | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 16/08/2022 | 14:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 13/08/2022 | 13:31 | TipRanks | Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA) | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 12/08/2022 | 15:30 | GlobeNewswire Inc. | Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update | NASDAQ:PCSA | Processa Pharmaceuticals Inc |
| 05/08/2022 | 21:00 | GlobeNewswire Inc. | Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST | NASDAQ:PCSA | Processa Pharmaceuticals Inc |